Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Ranibizumab Administered Monthly or on an As-Needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Study:

A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Rationale:

n/a

Purpose:

This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with CNV secondary to AMD.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Macular Degeneration Drug: ranibizumab
Drug: ranibizumab
Drug: ranibizumab
Drug: ranibizumab
Phase 3

Verified by Genentech November, 2010

Sponsored by: Genentech
Information provided by: Genentech
ClinicalTrials.gov identifier: NCT00891735

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Active Control, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Wendy Murahashi, M.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site